A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer.

Brief description of study

You can participate in this study if you are diagnosed with Cervical Cancer; Endometrial Cancer or Ovarian Cancer. The purpose of this study is to assess the Safety, Tolerability, and Efficacy of the study drug (XmAb®20717) in patients with selected advanced gynecologic and genitourinary tumors. The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on this medication during the entire study period.


Clinical Study Identifier: s22-00496
ClinicalTrials.gov Identifier: NCT05032040
Principal Investigator: Kari E. Hacker.
Other Investigators: Kent Chan, Jaime Lynn Moyles, Scot Niglio, Deanna Gerber, Eva Chalas-Westermann, Olivia Richardson Khouri, Hank Ng, Leslie R Boyd, Marina Stasenko, Fabia Brisard Pierrot, Alexander A Hindenburg, Caitlin Elizabeth Ryan, David R. Wise, Christina Grace Wilson, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Whitfield B. Growdon, Kelly A Levine, Victor Ricardo Adorno Febles, Edward A Jimenez, Erin Annette Reese, Bhavana Pothuri, Kathleen M Lutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.